サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1423795

皮膚糸状菌性爪白癬治療薬の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 治療タイプ別、適応症別、性別、年齢層別、エンドユーザー別、地域別

Dermatophytic Onychomycosis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日: | 発行: Fairfield Market Research | ページ情報: 英文 336 Pages | 納期: 2～5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
皮膚糸状菌性爪白癬治療薬の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 治療タイプ別、適応症別、性別、年齢層別、エンドユーザー別、地域別
出版日: 2024年01月25日
発行: Fairfield Market Research
ページ情報: 英文 336 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

世界の皮膚糸状菌性爪白癬治療薬の市場規模は、2024年から2031年にかけて大幅な成長が見込まれており、2031年末までに103億米ドルに達すると予測されています。

2021年には、皮膚糸状菌性爪白癬の治療に使用される薬剤が市場全体のシェアのほぼ4分の3を占め、43億6,000万米ドルと評価されました。この優位性は、この一般的な爪疾患に対処するための医薬品介入に大きく依存していることを強調しています。

皮膚糸状菌性爪白癬は世界人口の約10％が罹患しており、特に60歳以上の高齢者の有病率が高くなっています。その要因としては、末梢免疫疾患、血管疾患、糖尿病などが挙げられ、糖尿病患者のリスクは有意に高いものとなっています。さらに、有病率は地域によって異なり、熱帯アジア諸国では4～5％であるのに対し、欧州諸国では最大17％です。

皮膚糸状菌性爪白癬治療薬メーカーにとっては、診断や抗真菌検査に対する需要の高まりが追い風となり、予測期間中に大きなビジネスチャンスがもたらされます。医療従事者や患者の間で真菌性爪感染症に対する認識が高まり、進行中の臨床研究や医薬品パイプラインの開発と相まって、市場の成長をさらに促進すると予想されます。

当レポートでは、世界の皮膚糸状菌性爪白癬治療薬市場について調査し、市場の概要とともに、治療タイプ別、適応症別、性別、年齢層別、エンドユーザー別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の皮膚糸状菌性爪白癬治療薬市場の見通し、2018年～2031年

  • 世界の皮膚糸状菌性爪白癬治療薬市場の見通し、治療別、金額（10億米ドル）、2018年～2031年
  • 世界の皮膚糸状菌性爪白癬治療薬市場の見通し、適応症別、金額（10億米ドル）、2018年～2031年
  • 世界の皮膚糸状菌性爪白癬治療薬市場の見通し、性別、金額（10億米ドル）、2018年～2031年
  • 世界の皮膚糸状菌性爪白癬治療薬市場の見通し、年齢層別、金額（10億米ドル）、2018年～2031年
  • 世界の皮膚糸状菌性爪白癬治療薬市場の見通し、流通チャネル別、金額（10億米ドル）、2018年～2031年
  • 世界の皮膚糸状菌性爪白癬治療薬市場の見通し、地域別、金額（10億米ドル）、2018年～2031年

第4章 北米の皮膚糸状菌性爪白癬治療薬市場の見通し、2018年～2031年

第5章 欧州の皮膚糸状菌性爪白癬治療薬市場の見通し、2018年～2031年

第6章 アジア太平洋の皮膚糸状菌性爪白癬治療薬市場の見通し、2018年～2031年

第7章 ラテンアメリカの皮膚糸状菌性爪白癬治療薬市場の見通し、2018年～2031年

第8章 中東・アフリカの皮膚糸状菌性爪白癬治療薬市場の見通し、2018年～2031年

第9章 競合情勢

  • 製品と適応症のヒートマップ
  • 企業の市場シェア分析、2022年
  • 競合ダッシュボード
  • 企業プロファイル
    • Bausch Health
    • Galderma S.A.
    • Novartis AG
    • Pfizer, Inc.
    • Moberg Pharma AB
    • Bayer AG
    • Dr. Reddy's Laboratories Ltd.
    • Cipla Ltd.
    • Medimetriks Pharmaceuticals, Inc.
    • Sanofi S.A.
    • GlaxoSmithKline Plc.
    • Teva Pharmaceutical industries Ltd.

第10章 付録

目次

The global dermatophytic onychomycosis therapeutics market is poised for substantial growth from 2024 to 2031. According to the latest industry analysis by Fairfield Market Research, is anticipated to reach an impressive valuation of US$ 10.30 billion by the end of 2031.

Market Dominance of Drug Therapies

In 2021, drugs used for treating dermatophytic onychomycosis accounted for nearly three-fourths of the overall market share, valued at US$ 4.36 billion. This dominance underscores the significant reliance on pharmaceutical interventions to address this common nail disorder.

Global Prevalence and Contributing Factors

Dermatophytic onychomycosis affects approximately 10% of the global population, with higher prevalence rates among older adults, particularly those above 60 years of age. Contributing factors include peripheral immunologic disorders, vascular disease, and diabetes mellitus, with diabetic patients facing a significantly higher risk. Moreover, prevalence rates vary across regions, ranging from 4%-5% in tropical Asian countries to up to 17% in European countries.

Future Opportunities and Market Dynamics

The forecast period presents lucrative opportunities for dermatophytic onychomycosis therapeutic drug manufacturers, driven by rising demand for diagnosis and antifungal testing. Increased awareness of fungal nail infections among healthcare professionals and patients, coupled with ongoing clinical studies and developments in drug pipelines, are expected to further propel market growth.

Challenges and Constraints

Despite the promising outlook, challenges such as low elasticity of demand and the non-life-threatening nature of the condition restrain market growth to some extent. Treatment failures, recurrent infections, and competition from alternative therapies pose additional challenges for stakeholders in the dermatophytic onychomycosis therapeutics market.

Regional Insights

In the United States, frequent FDA approvals and the high prevalence of chronic diseases such as diabetes contribute to the country's leading market share. Germany benefits from the presence of major industry players, while China's market growth is fueled by collaborative research efforts and strategic expansions in medical infrastructure.

Key Market Drivers and Competitive Landscape

The drugs segment remains the primary driver of market growth, with distal subungual onychomycosis emerging as the most prevalent indication. Key manufacturers are focused on expanding their product portfolios, obtaining regulatory approvals, and forging strategic partnerships to enhance market presence and revenue streams.

Key Segments Covered in Dermatophytic Onychomycosis Therapeutics Industry Survey:

Dermatophytic Onychomycosis Therapeutics Market by Treatment Type:

  • Dermatophytic Onychomycosis Therapeutic Drugs
    • Oral
  • Rx
  • OTC
    • Topical
  • Rx
  • OTC
  • Dermatophytic Onychomycosis Therapeutic Lasers
    • C02 Ablative Lasers
    • Nd:YAG Lasers
    • Dual-wave length near-infrared Lasers
  • Photodynamic Therapy

Dermatophytic Onychomycosis Therapeutics Market by Indication:

  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Candidal Onychomycosis
  • Total Dystrophic Onychomycosis

Dermatophytic Onychomycosis Therapeutics Market by Gender:

  • Male
  • Female

Dermatophytic Onychomycosis Therapeutics Market by Age Group:

  • 0-18 Years
  • 18-39 Years
  • 40-64 Years
  • 65 Years and Above

Dermatophytic Onychomycosis Therapeutics Market by End User:

  • Institutional Sales
    • Hospitals
    • Dermatology Clinics
  • Retail Sales
    • Retail Pharmacies
    • Drug Stores
    • Mail Order Pharmacies & Online Sales

Dermatophytic Onychomycosis Therapeutics Market by Region:

  • North America Dermatophytic Onychomycosis Therapeutics Market
  • Latin America Dermatophytic Onychomycosis Therapeutics Market
  • Europe Dermatophytic Onychomycosis Therapeutics Market
  • South Asia Dermatophytic Onychomycosis Therapeutics Market
  • East Asia Dermatophytic Onychomycosis Therapeutics Market
  • Oceania Dermatophytic Onychomycosis Therapeutics Market
  • Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market

Table of Contents

1. Executive Summary

  • 1.1. Global Dermatophytic Onychomycosis Therapeutics Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031

  • 3.1. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Dermatophytic Onychomycosis Therapeutic Drugs
        • 3.1.1.1.1. Oral
          • 3.1.1.1.1.1. Rx
          • 3.1.1.1.1.2. OTC
        • 3.1.1.1.2. Topical
          • 3.1.1.1.2.1. Rx
          • 3.1.1.1.2.2. OTC
      • 3.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
        • 3.1.1.2.1. C02 Ablative Lasers
        • 3.1.1.2.2. Nd:YAG Lasers
        • 3.1.1.2.3. Dual-wavelength near-infrared Lasers
      • 3.1.1.3. Photodynamic Therapy
  • 3.2. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Distal Subungual Onychomycosis
      • 3.2.1.2. White Superficial Onychomycosis
      • 3.2.1.3. Proximal Subungual Onychomycosis
      • 3.2.1.4. Candidal Onychomycosis
      • 3.2.1.5. Total Dystrophic Onychomycosis
  • 3.3. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Male
      • 3.3.1.2. Female
  • 3.4. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. 0-18 Years
      • 3.4.1.2. 18-39 Years
      • 3.4.1.3. 40-64 Years
      • 3.4.1.4. 65 Years and Above
  • 3.5. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. Institutional Sales
        • 3.5.1.1.1. Hospitals
        • 3.5.1.1.2. Dermatology Clinics
      • 3.5.1.2. Retail Sales
        • 3.5.1.2.1. Retail Pharmacies
        • 3.5.1.2.2. Drug Stores
        • 3.5.1.2.3. Mail Order Pharmacies & Online Sales
  • 3.6. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.6.1. Key Highlights
      • 3.6.1.1. North America
      • 3.6.1.2. Europe
      • 3.6.1.3. Asia Pacific
      • 3.6.1.4. Latin America
      • 3.6.1.5. Middle East & Africa

4. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031

  • 4.1. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Dermatophytic Onychomycosis Therapeutic Drugs
        • 4.1.1.1.1. Oral
          • 4.1.1.1.1.1. Rx
          • 4.1.1.1.1.2. OTC
        • 4.1.1.1.2. Topical
          • 4.1.1.1.2.1. Rx
          • 4.1.1.1.2.2. OTC
      • 4.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
        • 4.1.1.2.1. C02 Ablative Lasers
        • 4.1.1.2.2. Nd:YAG Lasers
      • 4.1.1.3. Dual-wavelength near-infrared Lasers
  • 4.2. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Distal Subungual Onychomycosis
      • 4.2.1.2. White Superficial Onychomycosis
      • 4.2.1.3. Proximal Subungual Onychomycosis
      • 4.2.1.4. Candidal Onychomycosis
      • 4.2.1.5. Total Dystrophic Onychomycosis
  • 4.3. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Male
      • 4.3.1.2. Female
  • 4.4. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. 0-18 Years
      • 4.4.1.2. 18-39 Years
      • 4.4.1.3. 40-64 Years
      • 4.4.1.4. 65 Years and Above
  • 4.5. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. Institutional Sales
        • 4.5.1.1.1. Hospitals
        • 4.5.1.1.2. Dermatology Clinics
      • 4.5.1.2. Retail Sales
        • 4.5.1.2.1. Retail Pharmacies
        • 4.5.1.2.2. Drug Stores
        • 4.5.1.2.3. Mail Order Pharmacies & Online Sales
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis
  • 4.6. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.6.1. Key Highlights
      • 4.6.1.1. U.S. Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 4.6.1.2. U.S. Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.6.1.3. U.S. Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 4.6.1.4. U.S. Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 4.6.1.5. U.S. Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.6.1.6. Canada Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 4.6.1.7. Canada Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.6.1.8. Canada Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 4.6.1.9. Canada Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 4.6.1.10. Canada Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.6.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031

  • 5.1. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Dermatophytic Onychomycosis Therapeutic Drugs
        • 5.1.1.1.1. Oral
          • 5.1.1.1.1.1. Rx
          • 5.1.1.1.1.2. OTC
        • 5.1.1.1.2. Topical
          • 5.1.1.1.2.1. Rx
          • 5.1.1.1.2.2. OTC
      • 5.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
        • 5.1.1.2.1. C02 Ablative Lasers
        • 5.1.1.2.2. Nd:YAG Lasers
      • 5.1.1.3. Dual-wavelength near-infrared Lasers
  • 5.2. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Distal Subungual Onychomycosis
      • 5.2.1.2. White Superficial Onychomycosis
      • 5.2.1.3. Proximal Subungual Onychomycosis
      • 5.2.1.4. Candidal Onychomycosis
      • 5.2.1.5. Total Dystrophic Onychomycosis
  • 5.3. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Male
      • 5.3.1.2. Female
  • 5.4. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. 0-18 Years
      • 5.4.1.2. 18-39 Years
      • 5.4.1.3. 40-64 Years
      • 5.4.1.4. 65 Years and Above
  • 5.5. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Institutional Sales
        • 5.5.1.1.1. Hospitals
        • 5.5.1.1.2. Dermatology Clinics
      • 5.5.1.2. Retail Sales
        • 5.5.1.2.1. Retail Pharmacies
        • 5.5.1.2.2. Drug Stores
        • 5.5.1.2.3. Mail Order Pharmacies & Online Sales
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis
  • 5.6. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.6.1. Key Highlights
      • 5.6.1.1. Germany Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.6.1.2. Germany Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.6.1.3. Germany Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 5.6.1.4. Germany Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 5.6.1.5. Germany Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.6.1.6. U.K. Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.6.1.7. U.K. Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.6.1.8. U.K. Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 5.6.1.9. U.K. Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 5.6.1.10. U.K. Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.6.1.11. France Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.6.1.12. France Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.6.1.13. France Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 5.6.1.14. France Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 5.6.1.15. France Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.6.1.16. Italy Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.6.1.17. Italy Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.6.1.18. Italy Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 5.6.1.19. Italy Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 5.6.1.20. Italy Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.6.1.21. Turkey Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.6.1.22. Turkey Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.6.1.23. Turkey Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 5.6.1.24. Turkey Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 5.6.1.25. Turkey Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.6.1.26. Russia Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.6.1.27. Russia Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.6.1.28. Russia Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 5.6.1.29. Russia Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 5.6.1.30. Russia Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.6.1.31. Rest of Europe Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.6.1.32. Rest of Europe Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.6.1.33. Rest of Europe Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 5.6.1.34. Rest of Europe Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 5.6.1.35. Rest of Europe Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.6.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.1.1.1. Key Dermatophytic Onychomycosis Therapeutic Drugs
        • 6.1.1.1.1. Oral
          • 6.1.1.1.1.1. Rx
          • 6.1.1.1.1.2. OTC
        • 6.1.1.1.2. Topical
          • 6.1.1.1.2.1. Rx
          • 6.1.1.1.2.2. OTC
      • 6.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
        • 6.1.1.2.1. C02 Ablative Lasers
        • 6.1.1.2.2. Nd:YAG Lasers
    • 6.1.2. Dual-wavelength near-infrared Lasers
  • 6.2. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Distal Subungual Onychomycosis
      • 6.2.1.2. White Superficial Onychomycosis
      • 6.2.1.3. Proximal Subungual Onychomycosis
      • 6.2.1.4. Candidal Onychomycosis
      • 6.2.1.5. Total Dystrophic Onychomycosis
  • 6.3. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Male
      • 6.3.1.2. Female
  • 6.4. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. 0-18 Years
      • 6.4.1.2. 18-39 Years
      • 6.4.1.3. 40-64 Years
      • 6.4.1.4. 65 Years and Above
  • 6.5. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. Institutional Sales
        • 6.5.1.1.1. Hospitals
        • 6.5.1.1.2. Dermatology Clinics
      • 6.5.1.2. Retail Sales
        • 6.5.1.2.1. Retail Pharmacies
        • 6.5.1.2.2. Drug Stores
        • 6.5.1.2.3. Mail Order Pharmacies & Online Sales
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis
  • 6.6. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.6.1. Key Highlights
      • 6.6.1.1. China Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.6.1.2. China Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.6.1.3. China Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 6.6.1.4. China Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 6.6.1.5. China Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.6.1.6. Japan Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.6.1.7. Japan Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.6.1.8. Japan Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 6.6.1.9. Japan Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 6.6.1.10. Japan Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.6.1.11. South Korea Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.6.1.12. South Korea Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.6.1.13. South Korea Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 6.6.1.14. South Korea Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 6.6.1.15. South Korea Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.6.1.16. India Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.6.1.17. India Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.6.1.18. India Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 6.6.1.19. India Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 6.6.1.20. India Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.6.1.21. Southeast Asia Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.6.1.22. Southeast Asia Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.6.1.23. Southeast Asia Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 6.6.1.24. Southeast Asia Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 6.6.1.25. Southeast Asia Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.6.1.26. Rest of Asia Pacific Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.6.1.27. Rest of Asia Pacific Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.6.1.28. Rest of Asia Pacific Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 6.6.1.29. Rest of Asia Pacific Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 6.6.1.30. Rest of Asia Pacific Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.6.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031

  • 7.1. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Dermatophytic Onychomycosis Therapeutic Drugs
        • 7.1.1.1.1. Oral
          • 7.1.1.1.1.1. Rx
          • 7.1.1.1.1.2. OTC
        • 7.1.1.1.2. Topical
          • 7.1.1.1.2.1. Rx
          • 7.1.1.1.2.2. OTC
      • 7.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
        • 7.1.1.2.1. C02 Ablative Lasers
        • 7.1.1.2.2. Nd:YAG Lasers
      • 7.1.1.3. Dual-wavelength near-infrared Lasers
  • 7.2. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
      • 7.2.1.1. Distal Subungual Onychomycosis
      • 7.2.1.2. White Superficial Onychomycosis
      • 7.2.1.3. Proximal Subungual Onychomycosis
      • 7.2.1.4. Candidal Onychomycosis
      • 7.2.1.5. Total Dystrophic Onychomycosis
  • 7.3. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Male
      • 7.3.1.2. Female
  • 7.4. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. 0-18 Years
      • 7.4.1.2. 18-39 Years
      • 7.4.1.3. 40-64 Years
      • 7.4.1.4. 65 Years and Above
  • 7.5. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Institutional Sales
        • 7.5.1.1.1. Hospitals
        • 7.5.1.1.2. Dermatology Clinics
      • 7.5.1.2. Retail Sales
        • 7.5.1.2.1. Retail Pharmacies
        • 7.5.1.2.2. Drug Stores
        • 7.5.1.2.3. Mail Order Pharmacies & Online Sales
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis
  • 7.6. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.6.1. Key Highlights
      • 7.6.1.1. Brazil Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.6.1.2. Brazil Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.6.1.3. Brazil Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 7.6.1.4. Brazil Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 7.6.1.5. Brazil Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.6.1.6. Mexico Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.6.1.7. Mexico Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.6.1.8. Mexico Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 7.6.1.9. Mexico Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 7.6.1.10. Mexico Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.6.1.11. Argentina Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.6.1.12. Argentina Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.6.1.13. Argentina Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 7.6.1.14. Argentina Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 7.6.1.15. Argentina Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.6.1.16. Rest of Latin America Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.6.1.17. Rest of Latin America Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.6.1.18. Rest of Latin America Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 7.6.1.19. Rest of Latin America Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 7.6.1.20. Rest of Latin America Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.6.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Dermatophytic Onychomycosis Therapeutic Drugs
        • 8.1.1.1.1. Oral
          • 8.1.1.1.1.1. Rx
          • 8.1.1.1.1.2. OTC
        • 8.1.1.1.2. Topical
          • 8.1.1.1.2.1. Rx
          • 8.1.1.1.2.2. OTC
      • 8.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
        • 8.1.1.2.1. C02 Ablative Lasers
        • 8.1.1.2.2. Nd:YAG Lasers
      • 8.1.1.3. Dual-wavelength near-infrared Lasers
  • 8.2. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Distal Subungual Onychomycosis
      • 8.2.1.2. White Superficial Onychomycosis
      • 8.2.1.3. Proximal Subungual Onychomycosis
      • 8.2.1.4. Candidal Onychomycosis
      • 8.2.1.5. Total Dystrophic Onychomycosis
  • 8.3. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Male
      • 8.3.1.2. Female
  • 8.4. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. 0-18 Years
      • 8.4.1.2. 18-39 Years
      • 8.4.1.3. 40-64 Years
      • 8.4.1.4. 65 Years and Above
  • 8.5. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. Institutional Sales
        • 8.5.1.1.1. Hospitals
        • 8.5.1.1.2. Dermatology Clinics
      • 8.5.1.2. Retail Sales
        • 8.5.1.2.1. Retail Pharmacies
        • 8.5.1.2.2. Drug Stores
        • 8.5.1.2.3. Mail Order Pharmacies & Online Sales
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis
  • 8.6. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.6.1. Key Highlights
      • 8.6.1.1. GCC Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.6.1.2. GCC Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.6.1.3. GCC Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 8.6.1.4. GCC Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 8.6.1.5. GCC Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.6.1.6. South Africa Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.6.1.7. South Africa Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.6.1.8. South Africa Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 8.6.1.9. South Africa Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 8.6.1.10. South Africa Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.6.1.11. Egypt Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.6.1.12. Egypt Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.6.1.13. Egypt Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 8.6.1.14. Egypt Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 8.6.1.15. Egypt Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.6.1.16. Nigeria Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.6.1.17. Nigeria Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.6.1.18. Nigeria Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 8.6.1.19. Nigeria Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 8.6.1.20. Nigeria Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.6.1.21. Rest of Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.6.1.22. Rest of Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.6.1.23. Rest of Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 8.6.1.24. Rest of Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 8.6.1.25. Rest of Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.6.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Product vs Indication Heatmap
  • 9.2. Company Market Share Analysis, 2022
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Bausch Health
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Galderma S.A.
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Novartis AG
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Pfizer, Inc.
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Moberg Pharma AB
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Bayer AG
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Dr. Reddy's Laboratories Ltd.
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Cipla Ltd.
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Medimetriks Pharmaceuticals, Inc.
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Sanofi S.A.
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. GlaxoSmithKline Plc.
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Product Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development
    • 9.4.12. Teva Pharmaceutical industries Ltd.
      • 9.4.12.1. Company Overview
      • 9.4.12.2. Product Portfolio
      • 9.4.12.3. Financial Overview
      • 9.4.12.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations